Cargando…

The Present and Future of Neoadjuvant Endocrine Therapy for Breast Cancer Treatment

SIMPLE SUMMARY: The treatment of breast cancer has evolved considerably over the last two decades, leading toward individualized disease management. Hormone-sensitive breast cancers constitute the vast majority of cases and endocrine therapy is the mainstay of their treatment. On the other hand, neo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martí, Covadonga, Sánchez-Méndez, José Ignacio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8196711/ https://www.ncbi.nlm.nih.gov/pubmed/34064183 http://dx.doi.org/10.3390/cancers13112538

Ejemplares similares

Neoadjuvant endocrine therapy for luminal breast cancer treatment: a first-choice alternative in times of crisis such as the COVID-19 pandemic
por: Martí, Covadonga, et al.
Publicado: (2020)

Neoadjuvant endocrine therapy in breast cancer: current role and future perspectives
por: Barroso-Sousa, Romualdo, et al.
Publicado: (2016)

Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives
por: Barchiesi, Giacomo, et al.
Publicado: (2020)

The Clinical Impact of Neoadjuvant Endocrine Treatment on Luminal-like Breast Cancers and Its Prognostic Significance: Results from a Single-Institution Prospective Cohort Study
por: Martí, Covadonga, et al.
Publicado: (2022)

Neoadjuvant Endocrine Therapy in Breast Cancer Management: State of the Art
por: Lerebours, Florence, et al.
Publicado: (2021)

Neoadjuvant Chemotherapy and Targeted Therapy in Breast Cancer: Past, Present, and Future
por: Gampenrieder, Simon P., et al.
Publicado: (2013)

Neoadjuvant Chemotherapy for Breast Cancer: Past, Present, and Future
por: Asaoka, Mariko, et al.
Publicado: (2020)

Neoadjuvant endocrine therapy in ER-positive breast cancer: evolution, indication, and tailored treatment strategy
por: Jeong, Hyehyun, et al.
Publicado: (2023)

Neoadjuvant Endocrine Therapy (NET) in breast cancer – COVID setting
por: Bardoli, Antonio, et al.
Publicado: (2022)

Multidisciplinary Approach to Neoadjuvant Endocrine Therapy in Breast Cancer: A Comprehensive Review
por: Reinert, Tomás, et al.
Publicado: (2016)

The Present and Future of Neoadjuvant and Adjuvant Therapy for Locally Advanced Gastric Cancer
por: Koerner, Anna S., et al.
Publicado: (2023)

Surgical Interest of an Accurate Real-World Prediction of Primary Systemic Therapy Response in HER2 Breast Cancers
por: Sánchez-Méndez, Jose Ignacio, et al.
Publicado: (2023)

Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals
por: Szostakowska, Małgorzata, et al.
Publicado: (2018)

Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication
por: Ueno, Takayuki, et al.
Publicado: (2019)

Neoadjuvant treatment: the future of patients with breast cancer
por: Reyal, F, et al.
Publicado: (2018)

Statins and endocrine resistance in breast cancer
por: Hyder, Tara, et al.
Publicado: (2021)

Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkers
por: Selli, Cigdem, et al.
Publicado: (2016)

Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool
por: Chia, Y H, et al.
Publicado: (2010)

Neoadjuvant endocrine therapy in locally advanced estrogen or progesterone receptor-positive breast cancer: determining the optimal endocrine agent and treatment duration in postmenopausal women—a literature review and proposed guidelines
por: Madigan, Lauren I., et al.
Publicado: (2020)

Effect of Targeted Agents on the Endocrine Response of Breast Cancer in the Neoadjuvant Setting: A Systematic Review
por: Grassadonia, Antonino, et al.
Publicado: (2015)

Neoadjuvant Endocrine Therapy as an Alternative to Neoadjuvant Chemotherapy Among Hormone Receptor-Positive Breast Cancer Patients: Pathologic and Surgical Outcomes
por: Cao, Lifen, et al.
Publicado: (2021)

Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic
por: Park, Ko Un, et al.
Publicado: (2021)

The Role of Ki67 in Evaluating Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer
por: Zhang, Ailin, et al.
Publicado: (2021)

Network Meta-Analysis of the Effectiveness of Neoadjuvant Endocrine Therapy for Postmenopausal, HR–Positive Breast Cancer
por: Wang, Wei, et al.
Publicado: (2016)

Early metabolic response of breast cancer to neoadjuvant endocrine therapy: comparison to morphological and pathological response
por: Boughdad, Sarah, et al.
Publicado: (2020)

Biomarker Alteration after Neoadjuvant Endocrine Therapy or Chemotherapy in Estrogen Receptor-Positive Breast Cancer
por: Long, Mengping, et al.
Publicado: (2022)

Current treatment of early breast cancer: adjuvant and neoadjuvant therapy
por: Miller, Elizabeth, et al.
Publicado: (2014)

Present and future evolution of advanced breast cancer therapy
por: Álvarez, Ricardo H
Publicado: (2010)

The immunomodulatory effects of endocrine therapy in breast cancer
por: Huang, Huanhuan, et al.
Publicado: (2021)

Current concepts and future directions in neoadjuvant chemotherapy of breast cancer
por: Bartsch, Rupert, et al.
Publicado: (2018)

Status of adjuvant endocrine therapy for breast cancer
por: Schiavon, Gaia, et al.
Publicado: (2014)

Updates in endocrine therapy for metastatic breast cancer
por: Manohar, Poorni M., et al.
Publicado: (2022)

Clinical utility of the 21-gene assay in predicting response to neoadjuvant endocrine therapy in breast cancer: A systematic review and meta-analysis
por: Davey, M.G., et al.
Publicado: (2021)

Prolactin and endocrine therapy resistance in breast cancer: The next potential hope for breast cancer treatment
por: Li, Yuan, et al.
Publicado: (2021)

Contralateral parenchymal enhancement on breast MRI before and during neoadjuvant endocrine therapy in relation to the preoperative endocrine prognostic index
por: Ragusi, Max A. A., et al.
Publicado: (2020)

Aberrant Regulation of RAD51 Promotes Resistance of Neoadjuvant Endocrine Therapy in ER-positive Breast Cancer
por: Jia, Yan, et al.
Publicado: (2019)

A narrative review of primary research endpoints of neoadjuvant therapy for lung cancer: past, present and future
por: Ren, Sijia, et al.
Publicado: (2021)

Surgical Management of Axilla Following Neoadjuvant Endocrine Therapy
por: Murphy, Brenna M., et al.
Publicado: (2021)

Neoadjuvant systemic therapy for breast cancer
por: Zaborowski, Alexandra M, et al.
Publicado: (2023)

Novel Strategies to Improve the Endocrine Therapy of Breast Cancer
por: Castrellon, Aurelio Bartolome
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ul10h0k5iodil41h6op9ej0is3